1. Endocrine disorders among long-term survivors of childhood head and neck rhabdomyosarcoma.
- Author
-
Clement SC, Schoot RA, Slater O, Chisholm JC, Abela C, Balm AJM, van den Brekel MW, Breunis WB, Chang YC, Davila Fajardo R, Dunaway D, Gajdosova E, Gaze MN, Gupta S, Hartley B, Kremer LCM, van Lennep M, Levitt GA, Mandeville HC, Pieters BR, Saeed P, Smeele LE, Strackee SD, Ronckers CM, Caron HN, van Santen HM, and Merks JHM
- Subjects
- Adolescent, Adolescent Development, Adult, Age Factors, Child, Child Development, Child, Preschool, Cross-Sectional Studies, Female, Head and Neck Neoplasms surgery, Humans, Incidence, Infant, Infant, Newborn, Kaplan-Meier Estimate, Logistic Models, London epidemiology, Male, Multivariate Analysis, Netherlands epidemiology, Odds Ratio, Pituitary Diseases diagnosis, Pituitary Function Tests, Prevalence, Radiation Injuries diagnosis, Radiotherapy, Adjuvant, Retrospective Studies, Rhabdomyosarcoma surgery, Risk Factors, Time Factors, Treatment Outcome, Young Adult, Brachytherapy adverse effects, Cranial Irradiation adverse effects, Head and Neck Neoplasms radiotherapy, Pituitary Diseases epidemiology, Radiation Injuries epidemiology, Rhabdomyosarcoma radiotherapy, Survivors
- Abstract
Purpose: Head and neck rhabdomyosarcoma (HNRMS) survivors are at increased risk of developing pituitary dysfunction as an adverse event of radiotherapy. Our aim was to investigate the frequency and risk factors for pituitary dysfunction in these survivors. Secondly, we aimed to compare the prevalence of pituitary dysfunction between survivors treated with external beam radiation therapy (EBRT) and survivors treated with the ablative surgery, moulage technique after loading brachytherapy, and surgical reconstruction (AMORE) procedure., Methods: Eighty HNRMS survivors treated in London (EBRT based) and Amsterdam (AMORE based: AMORE if feasible, otherwise EBRT) in the period 1990-2010 and alive ≥ 2 years post-treatment were evaluated. Survivors were evaluated in multidisciplinary late-effects clinics, with measurement of linear growth, determination of thyroid function, and growth hormone parameters. Additional data, such as baseline characteristics, anthropometrics, pubertal stage, and the results of additional laboratory investigations, were retrieved from patient charts., Results: Pituitary dysfunction was diagnosed in 24 in 80 (30%) survivors, after a median follow-up time of 11 years. Median time to develop pituitary dysfunction after HNRMS diagnosis was 3.0 years. Risk factors were EBRT-based therapy (odds ratio [OR] 2.06; 95% confidence interval [CI] 1.79-2.46), parameningeal tumour site (OR 1.83; 95% CI 1.60-2.17) and embryonal RMS histology (OR 1.49; 95% CI 1.19-1.90)., Conclusions: Radiotherapy used for the treatment of HNRMS confers a significant risk of the development of pituitary dysfunction. AMORE-based treatment in children with HNRMS resulted in less pituitary dysfunction than treatment with conventional EBRT. Our findings underscore the importance of routine early endocrine follow-up in this specific population., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF